Page last updated: 2024-12-09

1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea is a **chemical compound**, and its importance lies in its potential **pharmacological activity**.

Here's a breakdown of its structure and potential uses:

**Structure:**

* **1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea** is a complex molecule with several distinct parts:
* **Phenyl rings:** Two benzene rings are present, one with a chlorine substituent (3-chlorophenyl) and the other with a substituted morpholine group.
* **Urea linkage:** The molecule is connected by a urea linkage, a common feature in many pharmaceutical compounds.
* **Morpholine group:** A morpholine ring (a heterocyclic ring containing oxygen and nitrogen) is attached to the second phenyl ring via an oxo (carbonyl) group.

**Potential Uses:**

This specific compound might have potential applications in the development of **drugs** due to its structural features. However, we need more information to understand its specific research significance:

* **Biological Target:** Knowing the **specific biological target** of the compound is crucial. Does it interact with receptors, enzymes, or other proteins involved in a particular biological pathway?
* **Pharmacological Activity:** What kind of **biological activity** does the compound exhibit? For example, does it demonstrate anti-inflammatory, antimicrobial, or analgesic properties?
* **Research Studies:** Has this compound been investigated in any **preliminary research studies**? Were its activity and safety evaluated in cell cultures or animal models?

**Importance in Research:**

The importance of 1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea in research would depend on the answers to the questions above.

* **If this compound shows promising biological activity**, it might become a lead compound for drug development, leading to new medications for a specific disease.
* **Even if it does not lead to a successful drug**, it could provide valuable insights into the structure-activity relationships of this chemical class, helping researchers design even more effective compounds in the future.

**To understand its importance, you need to know the specific research context.**

Let me know if you have more information about the compound, such as the research group studying it or its proposed use, and I can give you a more detailed answer.

Cross-References

ID SourceID
PubMed CID650428
CHEMBL ID1530583
CHEBI ID104991

Synonyms (25)

Synonym
CBMICRO_005435
HMS2579L23
BIM-0005332.P001
OPREA1_329376
OPREA1_269937
MLS000114212
smr000011048
1-(3-chloro-phenyl)-3-[4-(morpholine-4-carbonyl)-phenyl]-urea
MLS000070447 ,
CHEBI:104991
AKOS001624051
1-(3-chlorophenyl)-3-[4-(morpholine-4-carbonyl)phenyl]urea
smsf0013983
CB07514
1-(3-chlorophenyl)-3-(4-morpholin-4-ylcarbonylphenyl)urea
cid_650428
bdbm79638
1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea
CHEMBL1530583
Q27182661
SR-01000451287-1
sr-01000451287
389084-13-3
n-(3-chlorophenyl)-n'-[4-(4-morpholinylcarbonyl)phenyl]urea
DTXSID101187327
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.03160.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency15.47520.007215.758889.3584AID411; AID588342
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency11.22020.89137.722525.1189AID624202
TDP1 proteinHomo sapiens (human)Potency15.67580.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1468
Smad3Homo sapiens (human)Potency25.11890.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
P53Homo sapiens (human)Potency6.30960.07319.685831.6228AID504706
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
huntingtin isoform 2Homo sapiens (human)Potency11.22020.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cardiac alpha tropomyosinSus scrofa (pig)EC50 (µMol)71.48501.83002.37402.9180AID504698
troponin I, cardiac muscleHomo sapiens (human)EC50 (µMol)71.48501.83002.37402.9180AID504698
troponin T, cardiac muscle isoform 3Homo sapiens (human)EC50 (µMol)71.48501.83002.37402.9180AID504698
troponin C, slow skeletal and cardiac musclesHomo sapiens (human)EC50 (µMol)71.48501.83002.37402.9180AID504698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]